The return of biotech’s “bump factor” amid an economic downturn

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Hello, everyone. Damian here with a deep dive on a historic moment for genome editing, mixology tips from a biotech lifer, and a look at why scientists are interested in muscle-building drugs.

Everything you need to know about a historic moment in CRISPR
Scientific history is playing out before us. Yesterday, U.K. regulators approved Casgevy, the first-ever medicine to use CRISPR genome editing, just a decade after the revolutionary technology was just described.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

Log In